About the Company
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CBIO News
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced ...
Milestone Scientific Stock (AMEX:MLSS), Quotes and News Summary
Howmet Aerospace shares fell 0.1% to close at $45.98 on Friday. Gainers Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has ...
Building Connections: Blue Hen Executive Network
Grant Blouse, AS93, vice president of Catalyst Biosciences, Inc., enjoyed the interaction with his fellow alumni and appreciated hearing more about how he can become more engaged with his alma mater. ...
Cautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciences
Solid Biosciences (SLDB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 15. Analyst ...
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences, Inc. (NASDAQ:RNA) has a pretty extensive ... Should the data turn out to be positive, then this would be one catalyst that might cause the stock price to trade higher.
Catalyst, Inc.: CATALYST NAMES JENNIFER MCCOLLUM NEXT PRESIDENT & CEO
alongside the committed Catalyst staff, Board, and Supporters." McCollum most recently served as the CEO of Linkage, Inc., a SHRM company dedicated to advancing women and consistently ranked as a ...
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry ... nerve blocks and prepare for the significant catalyst ahead in NOPAIN. In parallel, we are taking ...
11 Best Small Cap Pharma Stocks to Invest In
We took a look, and some notable picks are Esperion Therapeutics, Inc. (NASDAQ:ESPR), Dynavax Technologies Corporation (NASDAQ:DVAX), and Pacira BioSciences, Inc. (NASDAQ:PCRX). A pharmaceutical ...
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript February 29, 2024 Pacira BioSciences, Inc. reports earnings inline with expectations.
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its ... in two key lower extremity nerve blocks and prepare for the significant catalyst ahead in ...
Q4 2023 Pacira Biosciences Inc Earnings Call
Reinhart; CFO; Pacira BioSciences, Inc. Frank D. Lee; CEO & Director ... which will be a solid tailwind for EXPAREL. We have a significant catalyst ahead in NOPAIN and then 2024, will be a key setup ...
Loading the latest forecasts...